Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 10/01/2011

    Nycomed: Daxas® included as a treatment option in COPD guidelines

    The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has included roflumilast (Daxas®) as a new treatment option in its COPD management guidelines. A section on the new class, phosphodiesterase 4 (PDE4) inhibitors, describes the efficacy of roflumilast in patients with COPD.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-daxas-included-as-a-treatment-option-in-copd-guidelines
  • Press release - 21/01/2010 European Molecular Biology Laboratory

    Open access drug discovery database launches with half a million compounds

    ChEMBLdb a vast online database of information on the properties and activities of drugs and drug-like small molecules and their targets was launched on January 18 2010 with information on over half a million compounds. The data lie at the heart of translating information from the human genome into successful new drugs in the clinic.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/open-access-drug-discovery-database-launches-with-half-a-million-compounds
  • Press release - 30/05/2012 10344_de.jpg

    Valuable Discussions at the Third International DDI Workshop

    The organisation team of the Third International DDI (drug-drug interactions) Workshop has expressed great satisfaction with the course of the scientific meeting. The participants of the DDI Workshop commended the very high scientific level of the presentations and valuable and inspiring discussions of the different topics. Without a doubt, the DDI Workshop at Marbach Castle is a well established platform for the annual exchange between experts,…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/valuable-discussions-at-the-third-international-ddi-workshop
  • Press release - 19/01/2010 10529_de.jpg

    Affimed Therapeutics AG Completes Move Into Drug Development

    Affimed Therapeutics AG, the therapeutic antibody company from Heidelberg, announced today that it is now concentrating all activities on the exclusive development of its in-house drug candidates derived from the company's proprietary TandAb technology platform. In line with this, the Company has spun-out its antibody discovery activities into a new company: AbCheck s.r.o, (Plzen, Czech Republic).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-therapeutics-ag-completes-move-into-drug-development
  • Press release - 19/11/2009 10171_de.jpg

    TET Systems and Novo Nordisk sign license agreement

    TET Systems Holding GmbH & Co. KG (“TET Systems”), a worldwide leader in controlled gene expression, today announced that TET Systems and Novo Nordisk A/S have signed a license agreement allowing the Hagedorn Research Institute (HRI), a research institute within Novo Nordisk A/S, the use of the Tet Technology for its internal research activities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tet-systems-and-novo-nordisk-sign-license-agreement
  • Press release - 25/06/2010 Ceremony to break the ground for the new Ravensburg facility Vetter West held on 18th June 2010. The photo shows Vetter's executive team and local representatives.

    Vetter to invest further millions in the construction of a modern centre for visual inspection and logistics in Ravensburg

    Ravensburg-based Vetter is expanding further. Last Friday, Vetter, a specialist in aseptically pre-filled drug-delivery systems, held a ceremony to break the ground for the construction of a new centre for visual inspection and logistics. Together with representatives from politics and industry, the company’s executives broke the ground for the new facility, which is estimated to cost more than 30 million euros. The construction of the new centre…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-to-invest-further-millions-in-the-construction-of-a-modern-centre-for-visual-inspection-and-l
  • Press release - 07/10/2020

    Joining forces against SARS-CoV-2

    Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/joining-forces-against-sars-cov-2
  • Article - 24/11/2010

    Choosing natural drugs is not without risk

    Germans like natural solutions and show a marked preference for medicines made from St. John’s wort, valerian, devil’s claw or Marian Thistle. However, when taking herbal medicines people are well advised to be cautious: "herbal" does not automatically mean safe, warns Thomas Simmet, pharmacologist from the University Hospital of Ulm.

    https://www.gesundheitsindustrie-bw.de/en/article/news/choosing-natural-drugs-is-not-without-risk
  • Article - 15/03/2010 10701_de.jpg

    Campaign to eradicate malaria

    After many decades, efforts to develop an effective vaccine against malaria have finally brought researchers closer to their goal. However, the goal of eradicating malaria completely can only be reached through a complex strategy, to which researchers from Heidelberg are making intensive contributions.

    https://www.gesundheitsindustrie-bw.de/en/article/news/campaign-to-eradicate-malaria
  • Article - 29/11/2008

    2008 Nycomed Award goes to three natural scientists

    Dr. Pitter Huesgen Dr. Michael Strerath and Dr. Carl Kübler have been awarded this years Nycomed Award. The Award which is worth a total of 15000 distinguishes outstanding doctoral theses in the fields of biology chemistry and physics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/2008-nycomed-award-goes-to-three-natural-scientists
  • Article - 26/04/2008

    Huge success for BioValley

    Organisers and more than 300 participants were very enthusiastic about the European BioFine life sciences congress recently held in Freiburg. Four different life sciences conferences were organised . Freiburg will also host BioFine 2009.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/huge-success-for-biovalley
  • Article - 04/02/2013 19110_de.jpg

    DKFZ-HIPO – the Heidelberg Center for Personalised Oncology

    The German Cancer Research Center (DKFZ) and the National Center for Tumour Diseases (NCT) have jointly initiated the Heidelberg Center for Personalised Oncology (HIPO) which provides cancer patients with high-throughput genetic and molecular analyses. In anticipation of the upcoming World Cancer Day on 4th February 2013, the potential of high-throughput genetic and molecular analyses in improving cancer therapy was presented at a workshop held…

    https://www.gesundheitsindustrie-bw.de/en/article/news/dkfz-hipo-the-heidelberg-center-for-personalised-oncology
  • Article - 02/09/2008

    Screening with high quality and high throughput

    The Early Discovery department of the research-based pharmaceutical company Nycomed GmbH deals with early drug research from the identification of targets to the generation of lead structures. This process involves high-throughput drug screening. On behalf of www.bio-pro.de Michael Statnik talked with Dr. Stefanie Polej about the process of the automated analysis of molecule activities in the Constance-based company.

    https://www.gesundheitsindustrie-bw.de/en/article/news/screening-with-high-quality-and-high-throughput
  • Press release - 04/05/2011 Vetter Logo

    Vetter’s Chicago Facility Now Accepting Projects

    Vetter, a leading provider of aseptic prefilled drug-delivery systems, announced that its Chicago facility is accepting client projects. Located at the Illinois Science + Technology Park in Skokie, Illinois, the site supports preclinical through phase II products.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-s-chicago-facility-now-accepting-projects
  • Article - 29/05/2012 17307_de.jpg

    Intestinal bacteria and human gut types

    The type of bacteria that colonize the human gut does not just influence our digestion and well-being. Metagenome sequencing has provided an international consortium involving scientists from the European Molecular Biology Laboratory at the University Hospital of Heidelberg with evidence that certain individuals have different gut types with different types of bacteria. Such individuals not only differ in their predisposition to disease, but also…

    https://www.gesundheitsindustrie-bw.de/en/article/news/intestinal-bacteria-and-human-gut-types
  • Press release - 18/11/2010

    NovAliX Acquires a Majority Interest in Graffinity Pharmaceutical GmbH

    Strasbourg, France based NovAliX SAS today announced that it has entered into a definitive agreement to acquire a majority interest in Graffinity Pharmaceuticals GmbH of Heidelberg, Germany, a leading fragment based drug discovery services company. Financial details of the transaction were not disclosed.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/novalix-acquires-a-majority-interest-in-graffinity-pharmaceutical-gmbh
  • Article - 11/02/2013 19222_de.jpg

    Quality management: burden or opportunity?

    Companies are facing increasing demands. Globalisation and an increasingly quality-conscious market increase competition and pricing pressure. To remain globally competitive companies need a product and service quality that will satisfy the customer in the long term. Alexander Cansier managing director of OrgaConnect GmbH has specialised in the support of small and medium-sized companies in the life sciences pharmaceutical and medical technology…

    https://www.gesundheitsindustrie-bw.de/en/article/news/quality-management-burden-or-opportunity
  • Press release - 08/10/2020

    New class of highly effective inhibitors protects against neurodegeneration

    Heidelberg neurobiologists decode central mechanism of degenerative processes in the brains of mouse models and develop new principle for therapeutic agents.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-class-highly-effective-inhibitors-protects-against-neurodegeneration
  • Press release - 29/06/2009 The photo shows a portait of a woman wearing glasses. The woman has long fair hair and is wearing a red pullover.

    Research Prize for Clinical Pharmacology in Ulm

    Julia Kirchheiner, a professor of Clinical Pharmacology at the Institute of Natural Medicine and Clinical Pharmacology, University of Ulm, in Germany, was awarded the Utrecht Award for Excellence in Pharmaceutical Research, 2009. The international prize is awarded once every two years to non-University of Utrecht scientists who have a proven record over years of excellent research vision and leadership of improving drug therapy or safety.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-prize-for-clinical-pharmacology-in-ulm
  • Article - 22/03/2010 10931_de.jpg

    IBR Inc.: Dual strategy for safe and effective drugs

    IBR Inc. a science-based provider of preclinical and clinical services specialises in inflammatory diseases. The analyses it carries out for the pharmaceutical and biotech sector help exclude potential side effects of specific drug candidates early in the development process.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ibr-inc-dual-strategy-for-safe-and-effective-drugs
  • Article - 13/02/2012 Passport photographs, one showing the face of a man with a beard, the second showing a man wearing glasses.

    Emcid Biotech GmbH: mosses as gold mines

    Mosses are a great source of molecules that offer protection against microorganisms dehydration and other stress factors but it is a potential that has yet to be fully exploited. Freiburg-based Emcid Biotech GmbH is developing a platform for the identification development and industrial production of natural substances and enzymes of lower plants in particular those of mosses.

    https://www.gesundheitsindustrie-bw.de/en/article/news/emcid-biotech-gmbh-mosses-as-gold-mines
  • Press release - 08/08/2012 Logo apogenix

    Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial

    The biopharmaceutical company Apogenix GmbH announced today that the phase II clinical proof of concept trial with APG101 as treatment of recurrent glioblastoma has met and exceeded expectations in the final analysis of the data. In this randomized controlled clinical study the patients were treated either with a combination of APG101 plus radiotherapy (APG101+RT group) or radiotherapy alone (RT group). The primary objective of the trial was to…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-apg101-exceeds-expectations-with-controlled-phase-ii-clinical-trial
  • Article - 17/10/2011 15524_de.jpg

    Papillomaviruses as cancer-causing agents and how they can be fought off

    Studies presented at the recent International Papillomavirus Conference in Berlin demonstrate that vaccination can prevent infection with the types of HPV that cause the majority of cervical cancers. New improved vaccines to prevent HPV infections as well as therapeutic vaccines that are effective in people that are already infected are currently being developed. In addition, research has shown that other cancers can also be caused by infective…

    https://www.gesundheitsindustrie-bw.de/en/article/news/papillomaviruses-as-cancer-causing-agents-and-how-they-can-be-fought-off
  • Dossier - 15/03/2010 09298_de.jpg

    Vaccine development

    As the recent discussion on the pros and cons of swine flu vaccinations has shown vaccinations are not very popular in Germany. However people tend to forget that no other medical development has helped people to the same extent as immunisation with vaccines has done. Examples include the discovery of the cow pox vaccination by Edward Jenner in 1796 and all the programmes that have been set up by the Global Alliance for Vaccines and Immunisation…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccine-development
  • Article - 07/01/2014 20806_de.jpg

    BioMed X GmbH - An innovation centre in Heidelberg at the interface between academia and industry

    BioMed X GmbH, founded in Heidelberg in March 2013, and Merck KGaA from Darmstadt have established a new way of fostering innovation at the interface of academic biomedical research and pharmaceutical industry-based research. Teams of top young and talented scientists from leading academic institutions worldwide carry out product-oriented research and development projects that are funded by the industry and for which they receive guidance from…

    https://www.gesundheitsindustrie-bw.de/en/article/news/biomed-x-gmbh-an-innovation-centre-in-heidelberg-at-the-interface-between-academia-and-industry

Page 5 / 8

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search